Helicobacter pylori

Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Helicobacter pylori.php on line 2
Helicobacter pylori

LE WE PMID CA

Helicobacter pylori

1120

Helicobacter pylori

Actin

Agrobacterium tumefaciens

Anemia (Iron deficiency anemia)

Antibiotics (Resistance)

Bacteria (Secretion type IV)

Biliary system (Diseases)

Cell migration

Coxiella burnetii

DNA (Methylation)

Dyspepsia

Gastroesophageal reflux disease

Ghrelin

Helicobacter pylori

Hydrogen breath tests

Legionella

Neoplasia (Carcinogenesis)

Nod1

ORL (Neoplasia)

Platelets (Idiopathic thrombocytopenia ITP)

Probiotica

Rickettsiella grylli

Stomach (Neoplasia)

Ulcus pepticum

2000 1	Regular review: treatment of Helicobacter pylori infection. [10617524] BMJ 320(7226): 31-4 (2000)
1997 2	Helicobacter pylori-associated gastroduodenal disease in childhood. [9191731] South Med J 90(6): 570-6; quiz 577 (1997)
1998 3	Current regimens for treatment of Helicobacter pylori infection. [9604443] Br Med Bull 54(1): 195-205 (1998)
1998 4	Microbiological and serological diagnostic tests for Helicobacter pylori: an overview. [9604441] Br Med Bull 54(1): 175-86 (1998)
1998 5	Interactions between H. pylori infection, gastric acid secretion and anti-secretory therapy. [9604437] Br Med Bull 54(1): 121-38 (1998)
1998 6	H. pylori virulence factors. [9604436] Br Med Bull 54(1): 105-20 (1998)
1998 7	Clinical significance of Helicobacter infection in children. [9604435] Br Med Bull 54(1): 95-103 (1998)
1998 8	Non-gastrointestinal consequences of Helicobacter pylori infection. [9604434] Br Med Bull 54(1): 87-93 (1998)
1998 9	Helicobacter pylori infection and gastric lymphoma. [9604433] Br Med Bull 54(1): 79-85 (1998)
1998 10	Helicobacter pylori infection and cancer. [9604432] Br Med Bull 54(1): 71-8 (1998)
1998 11	Helicobacter pylori infection and non-ulcer dyspepsia. [9604431] Br Med Bull 54(1): 63-9 (1998)
1998 12	Clinical science of Helicobacter pylori infection: ulcers and NSAIDs. [9604430] Br Med Bull 54(1): 55-62 (1998)
1998 13	Epidemiology of Helicobacter pylori: acquisition, transmission, population prevalence and disease-to-infection ratio. [9604429] Br Med Bull 54(1): 39-53 (1998)
1998 14	Helicobacter pylori--molecular genetics and diagnostic typing. [9604428] Br Med Bull 54(1): 31-8 (1998)
1998 15	Helicobacter--species classification and identification. [9604427] Br Med Bull 54(1): 17-30 (1998)
2000 16	Helicobacter pylori-related disease: guidelines for testing and treatment. [10809031] Arch Intern Med 160(9): 1285-91 (2000)
1999 17	Non-gastrointestinal tract associations of Helicobacter pylori infection. [10326935] Arch Intern Med 159(9): 925-40 (1999)
1998 18	Treatment of Helicobacter pylori infection. [9570169] Arch Intern Med 158(8): 842-51 (1998)
2005 19	A clinician's guide to managing Helicobacter pylori infection. [15757167] Cleve Clin J Med 72(2): 109-10, 112-3, 117-8 passim (2005)
2008 20	Helicobacter pylori--the latest in diagnosis and treatment. [18704207] Aust Fam Physician 37(8): 608-12 (2008)
2009 21	Helicobacter pylori and gastroduodenal ulcer disease. [20038978] Dtsch Arztebl Int 106(49): 801-8 (2009)
1998 22	Eradication of Helicobacter pylori infection in the management of patients with dyspepsia and non-ulcer dyspepsia. [10378358] Yale J Biol Med 71(2): 125-33 (1998)
1998 23	Treatment of H. pylori infection: the reality. [10378357] Yale J Biol Med 71(2): 119-24 (1998)
1998 24	Helicobacter pylori: therapeutic targets. [10378356] Yale J Biol Med 71(2): 113-7 (1998)
1998 25	Accuracy and economics of Helicobacter pylori diagnosis. [10378352] Yale J Biol Med 71(2): 75-9 (1998)
1998 26	Structure, function and localization of Helicobacter pylori urease. [10378351] Yale J Biol Med 71(2): 63-73 (1998)
1998 27	Helicobacter pylori and apoptosis. [10378350] Yale J Biol Med 71(2): 53-61 (1998)
1998 28	Pathobiology of Helicobacter pylori infection. [10378349] Yale J Biol Med 71(2): 43-51 (1998)
1996 29	Helicobacter pylori and its interaction with chief and parietal cells. [9041695] Yale J Biol Med 69(1): 91-8 (1996)
1996 30	Gastric MALT lymphoma and Helicobacter pylori. [9041690] Yale J Biol Med 69(1): 61-8 (1996)
1996 31	Helicobacter pylori: bacterial factors and interaction with the epithelial cells. [9041687] Yale J Biol Med 69(1): 35-7 (1996)
1992 32	Pathophysiology and clinical relevance of Helicobacter pylori. [1341068] Yale J Biol Med 65(6): 625-38 (1992)
2003 33	Diagnostic methods for Helicobacter pylori detection and eradication. [12919175] Br J Clin Pharmacol 56(3): 273-83 (2003)
1997 34	Eradication of Helicobacter pylori: an objective assessment of current therapies. [9088577] Br J Clin Pharmacol 43(3): 223-43 (1997)
2009 35	Helicobacter pylori infection in gastric cancerogenesis. [19826177] J Physiol Pharmacol 60(3): 3-21 (2009)
2006 36	Guidelines in the medical treatment of Helicobacter pylori infection. [17033112] J Physiol Pharmacol 57 Suppl 3(-): 143-54 (2006)
2001 37	Helicobacter pylori infection: epidemiology, pathophysiology, and therapy. [11794521] Arch Pharm Res 24(6): 485-98 (2001)
1999 38	Helicobacter pylori physiology predicted from genomic comparison of two strains. [10477312] Microbiol Mol Biol Rev 63(3): 675-707 (1999)
1999 39	Metabolism and genetics of Helicobacter pylori: the genome era. [10477311] Microbiol Mol Biol Rev 63(3): 642-74 (1999)
2007 40	Helicobacter pylori detection and antimicrobial susceptibility testing. [17428887] Clin Microbiol Rev 20(2): 280-322 (2007)
2006 41	Helicobacter pylori persistence: an overview of interactions between H. pylori and host immune defenses. [17041136] Clin Microbiol Rev 19(4): 597-613 (2006)
2006 42	Pathogenesis of Helicobacter pylori infection. [16847081] Clin Microbiol Rev 19(3): 449-90 (2006)
2001 43	Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases. [11148003] Clin Microbiol Rev 14(1): 59-97 (2001)
1997 44	Helicobacter pylori. [9336670] Clin Microbiol Rev 10(4): 720-41 (1997)
2009 45	Helicobacter pylori and gastric adenocarcinoma. [19874380] Clin Microbiol Infect 15(11): 971-6 (2009)
2009 46	Helicobacter pylori and gastric cancer: possible role of microRNAs in this intimate relationship. [19702585] Clin Microbiol Infect 15(9): 806-12 (2009)
2005 47	Pathogenicity of Helicobacter pylori infection. [16008611] Clin Microbiol Infect 11(8): 602-10 (2005)
2003 48	Non-invasive techniques for the diagnosis of Helicobacter pylori infection. [12848723] Clin Microbiol Infect 9(6): 489-96 (2003)
1998 49	Helicobacter pylori--a conundrum of genetic diversity. [9846728] Microbiology 144 ( Pt 11)(-): 2925-39 (1998)
2009 50	Helicobacter pylori's unconventional role in health and disease. [19855816] PLoS Pathog 5(10): e1000544 (2009)
2006 51	The diverse antioxidant systems of Helicobacter pylori. [16879643] Mol Microbiol 61(4): 847-60 (2006)
2000 52	Lewis antigens in Helicobacter pylori: biosynthesis and phase variation. [10931272] Mol Microbiol 36(6): 1187-96 (2000)
2007 53	Phagocytosis and persistence of Helicobacter pylori. [17346311] Cell Microbiol 9(4): 817-28 (2007)
2000 54	Helicobacter pylori: epidemiology and routes of transmission. [11218379] Epidemiol Rev 22(2): 283-97 (2000)
2007 55	Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. [17635369] Aliment Pharmacol Ther 26(3): 343-57 (2007)
2007 56	Meta-analysis: Helicobacter pylori eradication treatment efficacy in children. [17305754] Aliment Pharmacol Ther 25(5): 523-36 (2007)
2007 57	Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. [17229240] Aliment Pharmacol Ther 25(2): 155-68 (2007)
2007 58	Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer. [17229238] Aliment Pharmacol Ther 25(2): 133-41 (2007)
2006 59	Systematic review and meta-analysis: importance of CagA status for successful eradication of Helicobacter pylori infection. [16842453] Aliment Pharmacol Ther 24(2): 273-80 (2006)
2006 60	Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? [16611267] Aliment Pharmacol Ther 23(8): 1077-86 (2006)
2006 61	Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. [16393278] Aliment Pharmacol Ther 23(1): 35-44 (2006)
2005 62	A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. [15963079] Aliment Pharmacol Ther 22(1): 45-9 (2005)
2005 63	Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. [15948807] Aliment Pharmacol Ther 21(12): 1411-8 (2005)
2005 64	Controlled trial of interventions to increase testing and treatment for Helicobacter pylori and reduce medication use in patients with chronic acid-related symptoms. [15813839] Aliment Pharmacol Ther 21(8): 1029-39 (2005)
2005 65	Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication. [15709984] Aliment Pharmacol Ther 21(4): 341-5 (2005)
2005 66	Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. [15644050] Aliment Pharmacol Ther 21(1): 91-6 (2005)
2004 67	Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. [15569109] Aliment Pharmacol Ther 20(10): 1071-82 (2004)
2004 68	Review article: is there a link between micronutrient malnutrition and Helicobacter pylori infection? [15569104] Aliment Pharmacol Ther 20(10): 1029-34 (2004)
2004 69	Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection -- a critical review. [15569102] Aliment Pharmacol Ther 20(10): 1001-17 (2004)
2004 70	Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. [15379833] Aliment Pharmacol Ther 20(7): 733-44 (2004)
2004 71	Review article: Deoxyribonucleic acid-based diagnostic techniques to detect Helicobacter pylori. [15153166] Aliment Pharmacol Ther 19(11): 1137-46 (2004)
2003 72	Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists--their efficacy with antibiotics in Helicobacter pylori eradication. [14535868] Aliment Pharmacol Ther 18(8): 757-66 (2003)
2003 73	Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. [12969092] Aliment Pharmacol Ther 18(6): 647-54 (2003)
2003 74	Triple vs quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. [12950427] Aliment Pharmacol Ther 18(5): 543-4 (2003)
2003 75	Meta-analysis: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease. [12895212] Aliment Pharmacol Ther 18(3): 279-89 (2003)
2003 76	Review article: the treatment of refractory Helicobacter pylori infection. [12786627] Aliment Pharmacol Ther 17(11): 1333-43 (2003)
2003 77	Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. [12752350] Aliment Pharmacol Ther 17(9): 1137-43 (2003)
2003 78	Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. [12492738] Aliment Pharmacol Ther 17(1): 99-109 (2003)
2002 79	Alteration of histological gastritis after cure of Helicobacter pylori infection. [12390101] Aliment Pharmacol Ther 16(11): 1923-32 (2002)
2002 80	Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. [12144576] Aliment Pharmacol Ther 16(7): 1269-75 (2002)
2002 81	Review article: Helicobacter pylori infection and gastric outlet obstruction - prevalence of the infection and role of antimicrobial treatment. [12144568] Aliment Pharmacol Ther 16(7): 1203-8 (2002)
2002 82	Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. [12030945] Aliment Pharmacol Ther 16(6): 1047-57 (2002)
2002 83	Review article: Helicobacter species and hepatobiliary diseases. [12030944] Aliment Pharmacol Ther 16(6): 1037-45 (2002)
2002 84	Review article: an approach to Helicobacter pylori infection in the elderly. [11929385] Aliment Pharmacol Ther 16(4): 683-91 (2002)
2002 85	Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. [11876712] Aliment Pharmacol Ther 16(3): 569-75 (2002)
2002 86	Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. [11860399] Aliment Pharmacol Ther 16(2): 167-80 (2002)
2001 87	A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. [11736726] Aliment Pharmacol Ther 15(12): 1949-58 (2001)
2001 88	Review article: alternative antibacterial agents for Helicobacter pylori eradication. [11563992] Aliment Pharmacol Ther 15(10): 1543-7 (2001)
2001 89	pathogenesis of Helicobacter pylori-induced gastric inflammation. [11552897] Aliment Pharmacol Ther 15(9): 1271-90 (2001)
2001 90	Comparative efficacy of new investigational agents against Helicobacter pylori. [11284777] Aliment Pharmacol Ther 15(4): 487-92 (2001)
2000 91	Review article: the control of gastric acid and Helicobacter pylori eradication. [11069309] Aliment Pharmacol Ther 14(11): 1383-401 (2000)
2000 92	A systematic review of Helicobacter pylori eradication treatment schedules in children. [11050489] Aliment Pharmacol Ther 14 Suppl 3(-): 59-66 (2000)
2000 93	Treatment of Helicobacter pylori: an overview. [11050481] Aliment Pharmacol Ther 14 Suppl 3(-): 1-6 (2000)
1999 94	The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. [10383500] Aliment Pharmacol Ther 13(6): 719-29 (1999)
1999 95	Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management. [10102940] Aliment Pharmacol Ther 13(2): 117-27 (1999)
1998 96	Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. [9768524] Aliment Pharmacol Ther 12(9): 823-37 (1998)
2009 97	Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. [19183156] Aliment Pharmacol Ther 29(7): 720-30 (2009)
2008 98	Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. [18644011] Aliment Pharmacol Ther 28(7): 868-77 (2008)
2004 99	Histological aspects and role of mast cells in Helicobacter pylori-infected gastritis. [15298623] Aliment Pharmacol Ther 20 Suppl 1(-): 165-70 (2004)
2002 100	Review article: Helicobacter pylori infection from pathogenesis to treatment--a critical reappraisal. [12047269] Aliment Pharmacol Ther 16 Suppl 4(-): 105-13 (2002)
2002 101	Review article: natural history and epidemiology of Helicobacter pylori infection. [11849122] Aliment Pharmacol Ther 16 Suppl 1(-): 3-15 (2002)
1997 102	Review article: urea breath tests for detecting Helicobacter pylori. [9305471] Aliment Pharmacol Ther 11(4): 641-9 (1997)
1997 103	Gastric MALT-lymphoma and Helicobacter pylori infection. [9146794] Aliment Pharmacol Ther 11 Suppl 1(-): 89-94 (1997)
1997 104	Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer. [9146793] Aliment Pharmacol Ther 11 Suppl 1(-): 71-88 (1997)
2006 105	Genetic factors involved in the development of Helicobacter pylori-related gastric cancer. [16879717] Cancer Sci 97(11): 1129-38 (2006)
2005 106	Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis. [16367902] Cancer Sci 96(12): 835-43 (2005)
2005 107	Helicobacter pylori eradication: novel therapy for immune thrombocytopenic purpura? A review of the literature. [15682423] Am J Hematol 78(2): 142-50 (2005)
1999 108	Molecular and cellular activities of Helicobacter pylori pathogenic factors. [10376670] FEBS Lett 452(1-2): 16-21 (1999)
2006 109	Use and abuse of hydrogen breath tests. [16474100] Gut 55(3): 297-303 (2006)
2004 110	H pylori antibiotic resistance: prevalence, importance, and advances in testing. [15306603] Gut 53(9): 1374-84 (2004)
2002 111	The non-H pylori helicobacters: their expanding role in gastrointestinal and systemic diseases. [11788573] Gut 50(2): 273-83 (2002)
2001 112	Non-pylori Helicobacter species in humans. [11600455] Gut 49(5): 601-6 (2001)
1999 113	Extradigestive manifestations of Helicobacter pylori gastric infection. [10457029] Gut 45 Suppl 1(-): I9-I12 (1999)
1999 114	Are all helicobacters equal? Mechanisms of gastroduodenal pathology and their clinical implications. [10457027] Gut 45 Suppl 1(-): I1-4 (1999)
1998 115	Helicobacters are indigenous to the human stomach: duodenal ulceration is due to changes in gastric microecology in the modern era. [9824358] Gut 43(5): 721-7 (1998)
2009 116	Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication: a meta-analysis. [20027685] World J Gastroenterol 15(48): 6102-10 (2009)
2009 117	Comparative genomics of Helicobacter pylori. [19705492] World J Gastroenterol 15(32): 3984-91 (2009)
2008 118	"Rescue" regimens after Helicobacter pylori treatment failure. [18803350] World J Gastroenterol 14(35): 5385-402 (2008)
2006 119	Precise role of H pylori in duodenal ulceration. [17072972] World J Gastroenterol 12(40): 6413-9 (2006)
2006 120	Third-line rescue therapy for Helicobacter pylori infection. [16688818] World J Gastroenterol 12(15): 2313-9 (2006)
2006 121	Causal role of Helicobacter pylori infection and eradication therapy in gastric carcinogenesis. [16440410] World J Gastroenterol 12(1): 10-6 (2006)
2003 122	Helicobacter pylori. Pathology and diagnostic strategies. [12645343] Am J Clin Pathol 119(3): 403-12 (2003)
1997 123	Evolving therapy for Helicobacter pylori infection: efficacy and economic impact in the treatment of patients with duodenal ulcer disease. [10178459] Am J Manag Care 3(10): 1528-34 (1997)
2008 124	Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. [18490667] Ann Intern Med 148(12): 923-31 (2008)
2008 125	Sequential therapy for Helicobacter pylori: a worthwhile effort for your patients. [18490666] Ann Intern Med 148(12): 962-3 (2008)
2007 126	Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. [17938394] Ann Intern Med 147(8): 553-62 (2007)
2006 127	Improving Helicobacter pylori eradication regimens. [16418415] Ann Intern Med 144(2): 140-1 (2006)
2001 128	Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. [11242496] Ann Intern Med 134(5): 361-9 (2001)
1997 129	Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences. [9036800] Ann Intern Med 126(4): 280-91 (1997)
2009 130	Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection: a meta-analysis of randomized controlled trials. [20009394] Intern Med 48(24): 2069-76 (2009)
2000 131	Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori infection: evaluation of antibiotic treatment. [10801137] Intern Med 39(4): 273-4 (2000)
2004 132	Helicobacter pylori persistence: biology and disease. [14755326] J Clin Invest 113(3): 321-33 (2004)
1990 133	Helicobacter pylori (formerly Campylobacter pyloridis/pylori) 1986-1989: a review. [2196282] J Clin Pathol 43(5): 353-6 (1990)
2003 134	Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease. [14529149] Keio J Med 52(3): 163-73 (2003)
2000 135	Helicobacter pylori. [10684322] Postgrad Med J 76(893): 141-4 (2000)
1992 136	Eradication of Helicobacter pylori: therapies and clinical implications. [1437952] Postgrad Med J 68(801): 549-57 (1992)
1998 137	Procedure guideline for carbon-14-urea breath test. Society of Nuclear Medicine. [9829599] J Nucl Med 39(11): 2012-4 (1998)
1997 138	Helicobacter pylori: new developments and treatments. [9176424] CMAJ 156(11): 1565-74 (1997)
1994 139	Indications for treatment of Helicobacter pylori infection: a systematic overview. [8287341] CMAJ 150(2): 189-98 (1994)
1994 140	Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview. [8287340] CMAJ 150(2): 177-85 (1994)
2003 141	Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication. [12641497] Aliment Pharmacol Ther 17(6): 751-64 (2003)
2005 142	Events at the host-microbial interface of the gastrointestinal tract IV. The pathogenesis of Helicobacter pylori persistence. [15961885] Am J Physiol Gastrointest Liver Physiol 289(1): G8-12 (2005)
2004 143	Eradicating H pylori. [15191955] BMJ 328(7453): 1388-9 (2004)
2010 144	Association between helicobacter pylori and gastrointestinal symptoms in children. [20156901] Pediatrics 125(3): e651-69 (2010)
2010 145	First-line eradication of Helicobacter pylori: are the standard triple therapies obsolete? A different perspective. [20712046] World J Gastroenterol 16(31): 3865-70 (2010)
2011 146	Helicobacter pylori neutrophil activating protein as target for new drugs against H. pylori inflammation. [21677824] World J Gastroenterol 17(21): 2585-91 (2011)
2011 147	Molecular cross-talk between Helicobacter pylori and human gastric mucosa. [21472096] World J Gastroenterol 17(11): 1383-99 (2011)
2011 148	Endocrine impact of Helicobacter pylori: focus on ghrelin and ghrelin o-acyltransferase. [21455323] World J Gastroenterol 17(10): 1249-60 (2011)
2011 149	A new look at anti-Helicobacter pylori therapy. [22046084] World J Gastroenterol 17(35): 3971-5 (2011)
2007 150	Diet, H pylori infection and gastric cancer: evidence and controversies. [17589938] World J Gastroenterol 13(21): 2901-12 (2007)
2007 151	Emerging role of IL-23/IL-17 axis in H pylori-associated pathology. [17948927] World J Gastroenterol 13(42): 5547-51 (2007)
2005 152	Acid acclimation by Helicobacter pylori. [16287992] Physiology (Bethesda) 20(-): 429-38 (2005)
2010 153	Cytotoxic T cells in H. pylori-related gastric autoimmunity and gastric lymphoma. [20617132] J Biomed Biotechnol 2010(-): 104918 (2010)
2009 154	Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. [19729845] J Clin Invest 119(9): 2475-87 (2009)
2010 155	Role of innate immunity in Helicobacter pylori-induced gastric malignancy. [20664074] Physiol Rev 90(3): 831-58 (2010)
2007 156	The language used by Helicobacter pylori to regulate human cells. [17538876] J Infect Dis 196(1): 6-9 (2007)
2010 157	Helicobacter pylori and gastric cancer: factors that modulate disease risk. [20930071] Clin Microbiol Rev 23(4): 713-39 (2010)
2008 158	Use of NSAIDs and infection with Helicobacter pylori--what does the rheumatologist need to know? [18477642] Rheumatology (Oxford) 47(9): 1342-7 (2008)
2010 159	Iron deficiency anaemia can be improved after eradication of Helicobacter pylori. [20448223] Postgrad Med J 86(1015): 272-8 (2010)
2004 160	Eradication of Helicobacter pylori: a clinical update. [15208531] MedGenMed 6(1): 19 (2004)
2007 161	Type IV secretion system in Helicobacter pylori: a new insight into pathogenicity. [18167190] Chin Med J (Engl) 120(23): 2138-42 (2007)
2002 162	Risks and benefits of Helicobacter pylori eradication: current status. [11826340] Can J Gastroenterol 16(1): 57-62 (2002)
2011 163	Helicobacter pylori treatment in the hospital setting: a potential model for developing quality improvement initiatives to prevent missed test results. [22059157] Can J Gastroenterol 25(10): 542 (2011)
2004 164	Helicobacter pylori and the prevention of gastric cancer. [15152278] Can J Gastroenterol 18(5): 295-302 (2004)
2005 165	An update on anti-Helicobacter pylori treatment in children. [16010308] Can J Gastroenterol 19(7): 441-5 (2005)
2005 166	Noninvasive diagnostic tests for Helicobacter pylori infection in children. [16010307] Can J Gastroenterol 19(7): 433-9 (2005)
2005 167	Extradigestive manifestation of Helicobacter pylori infection in children and adolescents. [16010304] Can J Gastroenterol 19(7): 421-4 (2005)
2005 168	Modulation of host cell signal transduction pathways by Helicobacter pylori infection. [16010303] Can J Gastroenterol 19(7): 415-20 (2005)
2010 169	Helicobacter pylori infection, oncogenic pathways and epigenetic mechanisms in gastric carcinogenesis. [20465395] Future Oncol 6(5): 851-62 (2010)
2007 170	Helicobacter pylori in children: an Indian perspective. [17998576] Indian Pediatr 44(10): 761-70 (2007)
2009 171	Infection with Helicobacter pylori. Prevalence, research and impact of antibiotic resistance. [20001151] Rev Esp Enferm Dig 101(11): 743-56 (2009)
2006 172	Gastric angiogenesis and Helicobacter pylori infection. [17022702] Rev Esp Enferm Dig 98(7): 527-41 (2006)
2009 173	Current knowledge on helicobacter pylori infection in end stage renal disease patients. [19861855] Saudi J Kidney Dis Transpl 20(6): 969-74 (2009)
2011 174	Helicobacter pylori molecular diagnosis. [21545252] Expert Rev Mol Diagn 11(4): 351-5 (2011)
2002 175	Dental implications of Helicobacter pylori. [12323105] J Can Dent Assoc 68(8): 489-93 (2002)
2007 176	Helicobacter bilis: bacterial provocateur orchestrates host immune responses to commensal flora in a model of inflammatory bowel disease. [17566023] Gut 56(7): 898-900 (2007)
2007 177	The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. [17566020] Gut 56(10): 1353-7 (2007)
2007 178	Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. [17170018] Gut 56(6): 772-81 (2007)
2011 179	Should quinolones come first in Helicobacter pylori therapy? [21694812] Therap Adv Gastroenterol 4(2): 103-14 (2011)
2011 180	Type IVB Secretion Systems of Legionella and Other Gram-Negative Bacteria. [21743810] Front Microbiol 2(-): 136 (2011)
2010 181	Pleiotropic actions of Helicobacter pylori vacuolating cytotoxin, VacA. [20046046] Tohoku J Exp Med 220(1): 3-14 (2010)
2009 182	Efficient identification and evaluation of effective Helicobacter pylori therapies. [19026766] Clin Gastroenterol Hepatol 7(2): 145-8 (2009)
2010 183	Mechanisms of disease: Helicobacter pylori virulence factors. [20938460] Nat Rev Gastroenterol Hepatol 7(11): 629-41 (2010)
2010 184	Gastroesophageal Reflux Disease and Helicobacter pylori: What May Be the Relationship? [20680162] J Neurogastroenterol Motil 16(3): 243-50 (2010)
2011 185	What is the difference between Helicobacter pylori-associated dyspepsia and functional dyspepsia? [21602988] J Neurogastroenterol Motil 17(2): 124-30 (2011)
2011 186	How to interpret hydrogen breath tests. [21860825] J Neurogastroenterol Motil 17(3): 312-7 (2011)
2007 187	Helicobacter pylori: present status and future prospects in Japan. [17322988] J Gastroenterol 42(1): 1-15 (2007)
2009 188	Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. [19298338] Helicobacter 14(2): 109-18 (2009)
2006 189	Helicobacter pylori infection in pathogenesis of gastroesophageal reflux disease. [17033107] J Physiol Pharmacol 57 Suppl 3(-): 81-90 (2006)
2006 190	Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals. [17033106] J Physiol Pharmacol 57 Suppl 3(-): 67-79 (2006)
2006 191	Gastric cancer and Helicobacter pylori infection. [17033105] J Physiol Pharmacol 57 Suppl 3(-): 51-65 (2006)
2006 192	Helicobacter pylori and its involvement in gastritis and peptic ulcer formation. [17033104] J Physiol Pharmacol 57 Suppl 3(-): 29-50 (2006)
2006 193	Interplay between Helicobacter pylori and the immune system. Clinical implications. [17033103] J Physiol Pharmacol 57 Suppl 3(-): 15-27 (2006)
2006 194	Helicobacter pylori: microbiology and interactions with gastrointestinal microflora. [17033102] J Physiol Pharmacol 57 Suppl 3(-): 5-14 (2006)
2010 195	Management of Helicobacter pylori. [20948865] F1000 Med Rep 2(-): - (2010)
2007 196	Epigenetic field for cancerization. [17394762] J Biochem Mol Biol 40(2): 142-50 (2007)
2011 197	H. pylori exploits and manipulates innate and adaptive immune cell signaling pathways to establish persistent infection. [22044597] Cell Commun Signal 9(1): 25 (2011)
2011 198	Regulation of the actin cytoskeleton in Helicobacter pylori-induced migration and invasive growth of gastric epithelial cells. [22044652] Cell Commun Signal 9(1): 27 (2011)
2011 199	"Targeted disruption of the epithelial-barrier by Helicobacter pylori". [22044698] Cell Commun Signal 9(1): 29 (2011)
2007 200	Helicobacter pylori is invasive and it may be a facultative intracellular organism. [17388791] Cell Microbiol 9(5): 1108-16 (2007)
2010 201	NOD1-Mediated Mucosal Host Defense against Helicobacter pylori. [21152124] Int J Inflam 2010(-): 476482 (2010)
2005 202	Helicobacter pylori and gastric cancer: what can be learned by studying the response of gastric epithelial cells to the infection? [16103426] Cancer Epidemiol Biomarkers Prev 14(8): 1859-64 (2005)
2005 203	The biology of Helicobacter pylori infection, a major risk factor for gastric adenocarcinoma. [16103425] Cancer Epidemiol Biomarkers Prev 14(8): 1853-8 (2005)
2008 204	Helicobacter pylori in tonsillar and adenoid tissue and its possible role in oropharyngeal carcinogenesis. [18498719] Folia Biol (Praha) 54(2): 33-9 (2008)
2011 205	Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal. [21860834] World J Gastrointest Pathophysiol 2(3): 35-41 (2011)
2010 206	Worldwide H. pylori antibiotic resistance: a systematic review. [21188333] J Gastrointestin Liver Dis 19(4): 409-14 (2010)
PMC 207	A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. [24587620] World J Gastroenterol 20(6):1438-49 (2014)
PMC 208	Second-line and third-line trial for helicobacter pylori infection in patients with duodenal ulcers: A prospective, crossover, controlled study. [24764586] Curr Ther Res Clin Exp 65(1):13-25 (2004)
PMC 209	Helicobacter pylori and Systemic Disease. [24772167] Gastroenterol Res Pract 2014():358494 (2014)
PMC 210	Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan. [24764674] World J Gastroenterol 20(15):4362-9 (2014)
PMC 211	Does Helicobacter pylori protect against asthma and allergy? [18194986] Gut 57(5):561-7 (2008)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Helicobacter pylori.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Helicobacter pylori.php on line 92